Insight Molecular Diagnostics Details Progress on GraftAssureDx, Upcoming FDA Submission, and Strategic Partnership

summarizeSummary

Insight Molecular Diagnostics filed an investor presentation detailing its progress in molecular diagnostics, including upcoming FDA submission for its GraftAssureDx kidney transplant test, existing Medicare reimbursement, and a strategic partnership with Bio-Rad.

check_boxKey Events

• Anticipated FDA Submission

  The company expects to submit GraftAssureDx (kidney) for FDA IVD clearance for clinical use in early 2026, a critical step towards broader commercialization.

• Existing Medicare Reimbursement

  U.S. Medicare reimbursement for GraftAssureCore was received in 2023, with a listing of $2,753 per result, providing a clear revenue pathway.

• Strategic Partnership with Bio-Rad

  Insight Molecular Diagnostics has a strategic partnership with Bio-Rad Laboratories, an investor and platform provider, facilitating product development and market access.

• Revenue Generation Commenced

  Research Use Only (RUO) kits were launched in 2024, with revenue generation beginning in Q2 2025, demonstrating early market traction.

auto_awesomeAnalysis

This investor presentation outlines Insight Molecular Diagnostics' strategic vision to decentralize molecular diagnostic testing, emphasizing its GraftAssureDx product for transplant monitoring. The company highlights significant progress, including existing Medicare reimbursement for GraftAssureCore, the launch of RUO kits generating revenue, and an anticipated early 2026 FDA IVD submission for GraftAssureDx (kidney). The strategic partnership with Bio-Rad and the pursuit of a multi-billion dollar global market opportunity for kitted transplant testing are key drivers for future growth. The imminent FDA submission is a critical catalyst for the company's commercialization efforts.